Phosphorylation of kinase insert domain receptor by cyclindependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas

Oncotarget

Volumn 7, Issue 32, 2016, Pages 50883-50894

  Xie, Weiyan ^a,b   Liu, Chunhui ^b   Wu, Dan ^c   Li, Zhenye ^b   Li, Chuzhong ^a,b   Zhang, Yazhuo ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Beijing Ren he Hospital   (China)

Author keywords

CDK5; Invasiveness; KDR; Pathology Section; Phosphorylation; Prolactinomas

Indexed keywords

CYCLIN DEPENDENT KINASE 5; PROTEIN P35; SERINE; SERINE 229; UNCLASSIFIED DRUG; CDK5 PROTEIN, HUMAN; KDR PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; IMMUNOREACTIVITY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; ADULT; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROLACTINOMA; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; CYCLIN-DEPENDENT KINASE 5; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PITUITARY NEOPLASMS; PROGNOSIS; PROLACTINOMA; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84982313679     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10550     Document Type: Article

References (33)

1. Ghose A and Shashidhara LS. Cyclin beyond the cell cycle: new partners at the synapse. Developmental cell. 2011; 21(4):601-602.
2. Liu R, Tian B, Gearing M, Hunter S, Ye K and Mao Z. CDK5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(21):7570-7575.
3. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X and Linnoila RI. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through CDK5/p35 pathway. Molecular biology of the cell. 2012; 23(15):2856-2866.
4. Lin H, Chen MC, Chiu CY, Song YM and Lin SY. CDK5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. The Journal of biological chemistry. 2007; 282(5):2776-2784.
5. Liu JL, Gu RX, Zhou XS, Zhou FZ and Wu G. Cyclindependent kinase 5 regulates the proliferation, motility and invasiveness of lung cancer cells through its effects on cytoskeletal remodeling. Molecular medicine reports. 2015; 12(3):3979-3985.
6. Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG and Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Medical oncology (Northwood, London, England). 2011; 28(3):673-678.
7. Xie W, Wang H, He Y, Li D, Gong L and Zhang Y. CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression. International journal of biological sciences. 2014; 10 (2):192-199.
8. Di Ieva A, Grizzi F, Ceva-Grimaldi G, Aimar E, Serra S, Pisano P, Lorenzetti M, Tancioni F, Gaetani P, Crotti F, Tschabitscher M, Matula C, Rodriguez YBR (2010) The microvascular network of the pituitary gland: a model for the application of fractal geometry to the analysis of angioarchitecture and angiogenesis of brain tumors. J Neurosurg Sci 54:49-54
9. Di Ieva A, Grizzi F, Ceva-Grimaldi G, Aimar E, Serra S, Pisano P, Lorenzetti M, Tancioni F, Gaetani P, Crotti F, Tschabitscher M, Matula C and Rodriguez YBR. The microvascular network of the pituitary gland: a model for the application of fractal geometry to the analysis of angioarchitecture and angiogenesis of brain tumors. Journal of neurosurgical sciences. 2010; 54(2):49-54.
10. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK and Renner U. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. The Journal of endocrinology. 2006; 191(1):249-261.
11. Yamada S and Takada K. Angiogenesis in pituitary adenomas. Microscopy research and technique. 2003; 60(2):236-243.
12. Nomura R, Yoshida D and Teramoto A. Stromal cellderived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. Journal of neuro-oncology. 2009; 94(2):173-181.
13. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL and Wass JA. Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. The Journal of endocrinology. 2000; 165(2):475-481.
14. Luque GM, Perez-Millan MI, Ornstein AM, Cristina C and Becu-Villalobos D. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. The Journal of pharmacology and experimental therapeutics. 2011; 337(3):766-774.
15. Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B and Ince N. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ? Neuro endocrinology letters. 2010; 31(6):823-828.
16. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004; 56 (4):549-580.
17. Ochoa AL, Mitchner NA, Paynter CD, Morris RE and Ben-Jonathan N. Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. The Journal of endocrinology. 2000; 165(2):483-492.
18. Banerjee SK, Zoubine MN, Tran TM, Weston AP and Campbell DR. Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. International journal of oncology. 2000; 16(2):253-260.
19. Kim K, Yoshida D and Teramoto A. Expression of hypoxiainducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocrine pathology. 2005; 16(2):115-121.
20. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N and Shibuya M. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(4):1076-1081.
21. Meyer RD, Dayanir V, Majnoun F and Rahimi N. The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2/ FLK-1 regulates its autophosphorylation and activation of signaling molecules. The Journal of biological chemistry. 2002; 277(30):27081-27087.
22. Singh AJ, Meyer RD, Band H and Rahimi N. The carboxyl terminus of VEGFR-2 is required for PKC-mediated downregulation. Molecular biology of the cell. 2005; 16(4):2106-2118.
23. Vidal S, Lloyd RV, Moya L, Scheithauer BW and Kovacs K. Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. J Histochem Cytochem. 2002; 50(4):533-540.
24. Songyang Z, Lu KP, Kwon YT, Tsai LH, Filhol O, Cochet C, Brickey DA, Soderling TR, Bartleson C, Graves DJ, DeMaggio AJ, Hoekstra MF, Blenis J, Hunter T and Cantley LC. A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Molecular and cellular biology. 1996; 16(11):6486-6493.
25. Huang C, Rajfur Z, Yousefi N, Chen Z, Jacobson K and Ginsberg MH. Talin phosphorylation by CDK5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nature cell biology. 2009; 11(5):624-630.
26. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A and Nelkin BD. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer research. 2010; 70(11):4460-4469.
27. Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, Liu JO, Kachhap SK and Nelkin BD. Smallmolecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncology reports. 2014; 32(1):419-424.
28. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, Vollmar AM and Zahler S. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. The Journal of biological chemistry. 2010; 285(46):35932-35943.
29. Anthony A. Lanahan, Karlien Hermans, Filip Claes, Joanna S. Kerley-Hamilton, Zhen W. Zhuang, Frank J. Giordano, Peter Carmeliet and Michael Simons. VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell. 2011; 18 (5): 713-724.
30. Jeong J, Park YU, Kim DK, Lee S, Kwak Y, Lee SA, Lee H, Suh YH, Gho YS, Hwang D and Park SK. CDK5 phosphorylates dopamine D2 receptor and attenuates downstream signaling. PloS one. 2013; 8(12):e84482.
31. Delgrange E, Sassolas G, Perrin G, Jan M and Trouillas J. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta neurochirurgica. 2005; 147(7):751-757; discussion 757-758.
32. Wilson CB. A decade of pituitary microsurgery. The Herbert Olivecrona lecture. Journal of neurosurgery. 1984; 61(5):814-833.
33. Knosp E, Steiner E, Kitz K and Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4):610-617; discussion 617-618.